medicina61巻9号

2024年08月発行

特集 リウマチ膠原病疾患Up To Date！—押さえておきたい最新の診断と治療 膠原病の診断と治療

全身性エリテマトーデスの診断と治療—SLE分類基準，EULAR 2023治療推奨のポイントとSLE治療の今後の展望

著者： 中井健宏¹ 岡田正人¹

所属機関： ¹聖路加国際病院Immuno-Rheumatology Center

ページ範囲：P.1460 - P.1467

Point
◎全身性エリテマトーデス（SLE）治療においてはヒドロキシクロロキン（HCQ）投与が重要である．
◎SLE長期管理においては寛解を維持しステロイドを減量することで臓器障害を防ぐことが重要になる．
◎SLE治療においてステロイドの中止を目指すことがコンセンサスとなってきている．

参考文献

1）Kaul A, et al：Systemic lupus erythematosus. Nat Rev Dis Primers 2：16039, 2016 PMID 27306639

2）Peñaranda-Parada E, et al：Clinical, serologic, and immunogenetic characterization（HLA-DRB1）of late-onset lupus erythematosus in a Colombian population. Lupus 24：1293-1299, 2015 PMID 26022697

3）Hochberg MC：Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40：1725, 1997 PMID 9324032

4）Petri M, et al：Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64：2677-2686, 2012 PMID 22553077

5）Aringer M, et al：2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71：1400-1412, 2019 PMID 31385462

6）Arbuckle MR, et al：Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349：1526-1533, 2003 PMID 14561795

7）Adamichou C, et al：In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients；Use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis 79：232-241, 2020 PMID 31704720

8）Suda M, et al：Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in 100 Japanese patients；A real-world setting analysis. Clin Rheumatol 39：1823-1827, 2020 PMID 32052228

9）Fanouriakis A, et al：EULAR recommendations for the management of systemic lupus erythematosus；2023 update. Ann Rheum Dis 83：15-29, 2024 PMID 37827694

10）Fessler BJ, et al；LUMINA Study Group：Systemic lupus erythematosus in three ethnic groups；XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52：1473-1480, 2005 PMID 15880829

11）Hsu CY, et al：Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. Rheumatology（Oxford）57：1743-1751, 2018 PMID 29931367

12）Mates M, et al：Desensitization to hydroxychloroquine--experience of 4 patients. J Rheumatol 33：814-816, 2006 PMID 16463436

13）Jorge A, et al：Hydroxychloroquine retinopathy-implications of research advances for rheumatology care. Nat Rev Rheumatol 14：693-703, 2018 PMID 30401979

14）Furie R, et al：Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383：1117-1128, 2020 PMID 32937045

15）Rovin BH, et al：Efficacy and safety of voclosporin versus placebo for lupus nephritis（AURORA 1）；A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397：2070-2080, 2021 PMID 33971155

16）Fanouriakis A, et al：2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association（EULAR/ERA-EDTA）recommendations for the management of lupus nephritis. Ann Rheum Dis 79：713-723, 2020 PMID 32220834

17）Tamirou F, et al；MAINTAIN Nephritis Trial Group：Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 75：526-531, 2016 PMID 25757867

18）Jourde-Chiche N, et al；WIN-Lupus Study Group：Weaning of maintenance immunosuppressive therapy in lupus nephritis（WIN-Lupus）；Results of a multicentre randomised controlled trial. Ann Rheum Dis 81：1420-1427, 2022 PMID 35725295

19）Contreras G, et al：Sequential therapies for proliferative lupus nephritis. N Engl J Med 350：971-980, 2004 PMID 14999109

20）Morand EF, et al；TULIP-2 Trial Investigators：Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382：211-221, 2020 PMID 31851795

21）Navarra SV, et al；BLISS-52 Study Group：Efficacy and safety of belimumab in patients with active systemic lupus erythematosus；A randomised, placebo-controlled, phase 3 trial. Lancet 377：721-731, 2011 PMID 21296403

22）Furie R, et al；BLISS-76 Study Group：A phase Ⅲ, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63：3918-3930, 2011 PMID 22127708

23）Zhang F, et al：A pivotal phase Ⅲ, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77：355-363, PMID 29295825

24）Stohl W, et al：Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus；A fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69：1016-1027, 2017 PMID 28118533

25）Tanaka Y, et al：Rituximab in the real-world treatment of lupus nephritis；A retrospective cohort study in Japan. Mod Rheumatol 33：145-153, 2023 PMID 35165714

26）Gracia-Tello B, et al：The use of rituximab in newly diagnosed patients with systemic lupus erythematosus；Long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med 4：e000182, 2017 PMID 28243455

27）Murimi-Worstell IB, et al：Association between organ damage and mortality in systemic lupus erythematosus；A systematic review and meta-analysis. BMJ Open 10：e031850, 2020 PMID 32444429

28）Piga M, et al：Risk factors of damage in early diagnosed systemic lupus erythematosus；Results of the Italian multicentre Early Lupus Project inception cohort. Rheumatology（Oxford）59：2272-2281, 2020 PMID 31840179

29）Kernder A, et al：Delayed diagnosis adversely affects outcome in systemic lupus erythematosus；Cross sectional analysis of the LuLa cohort. Lupus 30：431-438, 2021 PMID 33402036

30）Kandane-Rathnayake R, et al；Asia-Pacific Lupus Collaboration：Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus；A prospective, multinational, longitudinal cohort study. Lancet Rheumatol 4：e822-e830, 2022 PMID 38261390

31）Zen M, et al：Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 77：104-110, 2018 PMID 28970217

32）Tarr T, et al：Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus. Clin Rheumatol 36：327-333, 2017 PMID 27889859

33）Mosca M, et al：Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 29：S126-S129, 2011 PMID 22018198

34）Mathian A, et al：Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year；A randomised clinical trial. Ann Rheum Dis 79：339-346, 2020 PMID 31852672

35）Tselios K, et al：Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol 3：550-557, 2021 PMID 34245233

36）Tani C, et al：Glucocorticoid withdrawal in systemic lupus erythematosus；Are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. RMD Open 5：e000916, 2019 PMID 31275608

37）Nakai T, et al：Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement；A single-center retrospective analysis. Lupus Sci Med 9：e000682, 2022 PMID 35654482